The impact of increased utilization of HIV drugs on longevity and medical expenditure: an assessment based on aggregate US time-series data

Abstract

The objective of this Special Report is to estimate the medical cost per life-year gained from increased utilization of HIV drugs by estimating the impact of increased drug utilization on the life expectancy and drug and hospital expenditure of HIV/AIDS patients, using aggregate (US national-level) data for the period 1982–2001.

Keywords::

• HIV/AIDS
• hospitalization
• innovation
• life expectancy
• medical expenditure
• mortality
• pharmaceuticals

Acknowledgement

The research was supported by Abbott Laboratories (IL, USA). The publication of study results was not contingent on the sponsor’s approval or censorship of the manuscript.